Broomfield, CO – January 24, 2025 (NewMediawire) – Aclarion, Inc., (Aclarion or the Company) (Nasdaq: Acon, Aconw), a health care technology company that exploits biomarkers and exclusive intelligence algorithms increased increased intelligence To help doctors identify the location. Chronic low back pain, announced today that from the opening of the markets on Wednesday, January 29, 2025, he will carry out a grouping of actions of 1 for 370 of his ordinary actions.
On December 31, 2024, the shareholders of the company approved a modification of the certificate of constitution of the company in order to bring together a grouping of shares whose exact ratio will be fixed by its board of directors. The council decided to set the grouping of shares at the ratio of 1 for 370. The company filed a modification of its certificate of constitution with the Secretary of State of Delaware from January 28, 2025, at 5:00 p.m. from the East. Consequently, all three hundred and seventies (370) ordinary actions issued will be automatically grouped into one (1) ordinary action.
The company estimates that the regrouping of shares will help it in its efforts to meet the continuous rating standards of the NASDAQ and to continue that its ordinary shares remain listed and negotiated at the NASDAQ. In particular, the company expects the grouping of shares to increase the price per share and the buyer price of its ordinary shares above $ 1.00 required by the minimum NASDAQ buyer price rule.
The company’s ordinary shares will be awarded a new CUSIP number (655187300) and should start to be negotiated on a basis adjusted according to fractionation on Wednesday January 29, 2025.
The grouping of shares will not modify the authorized number of ordinary shares of the company. No action breaks will be issued and the actions of shares resulting from the grouping of shares will be rounded up to the closest all action. Consequently, shareholders holding less than 370 actions will receive action.
The grouping of shares will apply to subscription vouchers, share purchase options and limited action units in the circulation of the company. The number of ordinary shares in which these securities in circulation are convertible or exercised will be adjusted proportionally following the grouping of shares. The conversion or exercise prices of any subscription vouchers or purchase options in circulation will also be adjusted proportionately in accordance with the conditions of these securities and the company’s profit -sharing plans.
Once the grouping of shares is effective, shareholders holding shares via a brokerage account will see their actions automatically adjusted to reflect the grouping of shares of 1 for 370. Existing shareholders holding ordinary action certificates will receive a Letter of sending the Aclary Transfer Agent, VSTOCT Transfer, with specific instructions concerning the exchange of shares.
The company provides that its ordinary shares issued and in circulation will drop from around 185 million shares before splitting around 500,000 shares in circulation after the fractionation following the grouping of shares.
About Aclarion, Inc.
Aclarion is a health care technology company that uses magnetic resonance spectroscopy (MRS), exclusive signal processing techniques, biomarkers and increased intelligence algorithms to optimize clinical treatments. The company first tackles the chronic low back pain market with Nociscan, the first SaaS platform based on convincing data to help doctors in a non -invasive manner to distinguish between the painful and non -painful discs of the lumbar column. Thanks to a cloud connection, Nociscan receives the magnetic resonance spectroscopy data (MRS) of an MRI device for each lumbar disc evaluated. In the Cloud, exclusive signal processing techniques extract and quantify the chemical biomarkers associated with discount pain. Biomarkers data is entered in exclusive algorithms to indicate whether a disk can be a pain source. When used with other diagnostic tools, Nociscan provides essential information on the location of a patient’s back pain, thus giving doctors the clarity necessary to optimize treatment strategies. For more information, please visit www.aclarion.com – opens in a new window.
Prospective declarations
This press release contains prospective declarations within the meaning of the Private Securities Litigation Reform Act of 1995, article 27a of the Securities Act of 1933 and article 21st of the EXCHANGE ACT SECURITIES of 1934 concerning the current expectations of The company concerning results, performance, perspectives and opportunities. Declarations that are not historical facts, such as “anticipates”, “believes” and “expects” or similar expressions, are prospective declarations. These prospective declarations are based on the current management levels and expectations and are subject to a certain number of uncertainties and risks which could significantly affect the current plans and expectations of the company, as well as the operating results and the future financial situation. These risks and uncertainties, as well as others, are addressed in more detail in our documents deposited with the Securities and Exchange Commission. Readers are encouraged to consult the section entitled “Risk factors” in the company’s annual report on form 10-K for the year ended December 31, 2023, as well as the other information contained in the prospectus and the documents deposited later with the Securities and Exchange Commission. . The prospective statements contained in this advertisement are made on this date and the company does not undertake in any way to update or publicly revise the prospective declarations, whether following new information, future events or otherwise.
Investor contacts:
Kirin M. Smith
CEO Consulting, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media contacts:
Jodi Lamberti
Sprig advice
612,812,7477
jodi@sprigconsulting.com
Copyright 2025 JCN press wire. All rights reserved.
